Wegovy vs Ozempic in 2026: same drug, different prescribing rules

Same molecule, different label

Wegovy and Ozempic are both injectable semaglutide manufactured by Novo Nordisk. Same active ingredient, same mechanism (GLP-1 receptor agonist), same adverse-effect profile. The difference is exclusively regulatory: Wegovy is FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Ozempic is FDA-approved for type 2 diabetes with the secondary indication of reducing major cardiovascular events in T2D patients with established cardiovascular disease.

The split exists because the FDA approved the two indications separately, with separate dose ranges and separate marketing. The clinical evidence comes from different trial programs: STEP-1 through STEP-5 for Wegovy in weight management; SUSTAIN-1 through SUSTAIN-10 for Ozempic in T2D. Same molecule, different evidence base, different regulatory permissions for what prescribers can write the drug for.

Dose differences

Wegovy dose ladder: 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg weekly, titrated every 4 weeks. Maintenance dose 2.4mg.

Ozempic dose ladder: 0.25mg → 0.5mg → 1.0mg → 2.0mg weekly, also titrated every 4 weeks. Maintenance is typically 1.0mg or 2.0mg depending on glycemic response.

Key clinical point: most weight-loss trials show better results at 2.4mg vs 2.0mg. If a patient gets prescribed Ozempic off-label for weight loss, they'll often plateau at the 2.0mg ceiling and miss the additional ~3-4% loss available at the FDA-approved Wegovy 2.4mg dose. This is the cleanest argument for switching from off-label Ozempic to FDA-approved Wegovy when the indication is weight management.

Insurance pathways differ substantially

Ozempic insurance coverage is broad — type 2 diabetes is on every major formulary and PA requirements are usually documentation of T2D + A1C. Most commercial plans cover Ozempic for T2D with $25-50 copay after PA.

Wegovy insurance coverage varies enormously. Many commercial employer plans exclude obesity medications entirely. Where covered, PA typically requires BMI ≥30 (or ≥27 with comorbidity), often a step-therapy requirement of 6+ months of lifestyle intervention, and prescriber attestation. Medicare does not cover weight-loss-only GLP-1s in 2026 (proposed Treat a Reduce Obesity Act would change this — not yet enacted).

This creates the perverse situation where patients with both obesity and T2D get prescribed Ozempic instead of Wegovy purely because insurance covers the diabetes indication. The clinical evidence supports Wegovy at higher dose for weight loss, but the insurance pathway pushes toward Ozempic.

Cost comparison

Retail pharmacy list price: ~$1,349 per 28-day supply for either drug at any dose. The brands are priced identically.

Commercial insurance with PA: typically $0-50/mo copay for both.

Cash-pay paths: NovoCare self-pay program offers Wegovy at $499/mo for eligible cash patients. No equivalent cash-pay program for Ozempic — patients without coverage pay close to retail or use GoodRx (small discount).

For self-pay weight-loss patients, Wegovy through NovoCare is dramatically cheaper than Ozempic at retail. For self-pay T2D patients, paths are limited — patient assistance programs (NovoCare PAP) or manufacturer copay cards may apply.

When prescribers choose Wegovy vs Ozempic

Prescribers choose Wegovy when: primary indication is weight management; patient meets BMI criteria; insurance covers it or patient can afford NovoCare; dose escalation to 2.4mg is clinically appropriate.

Prescribers choose Ozempic when: patient has T2D; insurance covers it cleanly; patient also wants weight loss as secondary benefit (off-label dose stays at 2.0mg max but coverage is easier).

Increasingly common pattern: T2D + obesity patients start on Ozempic for coverage reasons, then their physician requests Wegovy formulary exception once initial response is documented. This dual-track approach gets the higher dose ceiling without losing insurance coverage entirely.

Switching between them

Patients who get bumped from one to the other (insurance change, off-label clarification) can switch without re-titrating, as long as the same dose is available on the new brand. Going from Ozempic 1.0mg to Wegovy 1.0mg is a same-dose switch. Going from Ozempic 2.0mg to Wegovy 2.4mg requires one more titration step (1.7mg in between).

Note that the pen design and dose dial differ slightly between brands. Patients should watch the manufacturer instruction video for the new brand even if they've been injecting semaglutide for years.